Skip to main content
editor@jprims.in
9343055451
e-ISSN: 3049-1681
Journal of Pharmaceutical Research and Integrated Medical Sciences

Journal of Pharmaceutical Research and Integrated Medical Sciences

📢 Latest Update: New special issue call for papers on "Pharmaceutical Research and Integrated Medical Sciences" - Submit by September 30, 2026

📢 Latest Update: New special issue call for papers on "Pharmaceutical Research and Integrated Medical Sciences" - Submit by September 30, 2026

Volume 3, Issue 11 - 2026 (JPRIMS, Vol-3, Issue-11, November-2026)

Volume 3 Issue 11 Cover

Issue Details:

Volume 3 Issue 11
Published:Nov 17, 2026

Editorial: JPRIMS, Vol-3, Issue-11, November-2026

Welcome to the 2026 issue of Journal of Pharmaceutical Research and Integrated Medical Sciences. This issue showcases the remarkable breadth and depth of contemporary research across multiple disciplines. From cutting-edge applications of machine learning in climate science to the revolutionary potential of quantum computing in drug discovery, our featured articles demonstrate the power of interdisciplinary collaboration in addressing global challenges.

We are particularly excited to present research that bridges traditional academic boundaries, reflecting our journal's commitment to fostering innovation through cross-disciplinary dialogue. The integration of artificial intelligence with environmental science, the application of blockchain technology to supply chain management, and the convergence of urban planning with smart city technologies exemplify the transformative potential of collaborative research.

As we continue to navigate an era of rapid technological advancement and global challenges, the research presented in this issue offers both insights and solutions that will shape our future. We thank our authors, reviewers, and editorial board members for their continued dedication to advancing knowledge and promoting scientific excellence.

Dr. Arpan Kumar Tripathi
Editor in Chief
Journal of Pharmaceutical Research and Integrated Medical Sciences

Articles in This Issue

Showing 2 of 2 articles
Research PaperID: JPRIMS1130001Pages 1-26Open AccessOpen Access

Hypoglycemic Effect of Methanolic Extract of Annona Squmosa L. (Seeds) on Streptozotocin-Induced Diabetes in Rats

Bhulaxmi, Arpan Kumar Tripathi

The purity, safety, and long-term therapeutic efficacy of Annona squamosa L. seed extract in the treatment of diabetes were thoroughly assessed. Petroleum ether defatting and Soxhlet methanolic extraction came with the establishment of physicochemical standards (ash values). High levels of total phenolic content (TPC) and total flavonoid content (TFC), which provided notable in vitro antioxidant and anti-glycation properties, were shown by quantitative phytochemical screening. According to OECD Guideline 420 (Fixed Dose Procedure), acute oral toxicity testing verified that the extract has a broad margin of safety, showing no evidence of acute toxicity or fatality up to the highest suggested limit dose. Oral administration of Annona squamosa L. seed extract (200 mg/kg and 400 mg/kg) significantly decreased fasting blood glucose levels and reversed progressive body weight loss in an 8-week in vivo study on streptozotocin (STZ, 50–55 mg/kg)-induced diabetic Wistar rats when compared to untreated diabetic controls. The therapeutic efficacy of the 400 mg/kg dose was similar to that of normal Glibenclamide (10 mg/kg). To sum up, Annona squamosa L. seed methanolic extract is a safe, flavonoid-rich, antioxidant-rich substance that successfully reduces glycation, hyperglycemia, and weight loss in people with chronic diabetes.

Annona squamosa L.Methanolic ExtractionTPCTFCAntioxidant ActivityIn-Vitro Antiglyction Activity+2 more
21,667 views
6,593 downloads

Contributors:

 Bhulaxmi
,
 Arpan Kumar Tripathi
Research PaperID: JPRIMS1130002Pages 27-40Open AccessOpen Access

Ethanolic Leaf Extract of Chenopodium album Linn. Attenuates Calcium Oxalate-Associated Urolithiasis in Rats: An Integrated In Vitro and In Vivo Evaluation

Arpan Kumar Tripathi, Yashika, Deleshwar Kumar

Background: The primary stone component in urolithiasis, a recurrent urinary tract disease characterized by crystal nucleation, development, aggregation, and retention, is calcium oxalate (CaOx). Chenopodium album Linn. has a long history of ethnomedical use for urinary and renal issues and has demonstrated an initial anti-crystallization effect. However, little information is known about the relationship between in vivo renal and urinary outcomes and in vitro CaOx crystallization. Objective: This study evaluated the anti-urolithiatic potential of an ethanolic leaf extract of C. album (EECA) using complementary in vitro and in vivo techniques. Methods: The leaves were subjected to Soxhlet extraction using ethanol to obtain a 6.0% w/w extract, and preliminary phytochemical screening was carried out. The nucleation of CaOx was measured at 10–100 mg/mL, and the inhibition of crystal growth was also examined. The standard treatment was cystone (750 mg/kg). EECA was given at doses of 50 and 200 mg/kg to rats with urolithiasis associated with calcium oxalate. Urinary uric acid, urine volume, and renal histology were determined. Results: EECA inhibited CaOx nucleation in a concentration-dependent manner by 18.75% at 10 mg/mL and 77.50% at 100 mg/mL. Inhibition at 100 mg/mL exceeded the observed Cystone response of 72.50%. EECA also raised urine production and reduced urinary uric acid, particularly at 200 mg/kg. The results of the histopathology showed improved kidney structure. Conclusion: EECA demonstrated anti-crystallization and protective qualities in experimental urolithiasis, encouraging further mechanistic, phytochemical-standardizing, and translational research.

Chenopodium albumcalcium oxalateurolithiasisnucleationcrystallizationCystone+3 more
21,674 views
6,548 downloads

Contributors:

 Arpan Kumar Tripathi
,
 Yashika
,
 Deleshwar Kumar